---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-266722"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T05:13:21.389067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA eligible for $5M milestone from FDA acceptance of Day One's NDA for tovorafenib in pediatric glioma

## Summary
- FDA accepted Day One Biopharmaceuticals' NDA for tovorafenib as monotherapy for relapsed/progressive pediatric low-grade glioma.
- XOMA now eligible for a $5 million milestone payment from Day One under the tovorafenib royalty purchase agreement.
- XOMA originally acquired up to $54M in milestones and mid-single digit royalties on tovorafenib from Viracta in March 2021.

## SEC filing metadata
- accession: 0001193125-23-266722
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523266722/0001193125-23-266722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523266722/d569726d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-266722
- JSON: https://secwatch.observer/filing/0001193125-23-266722.json
- Plain text: https://secwatch.observer/filing/0001193125-23-266722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.